一分钟看懂
这是一项关于卵巢癌的III 期研究，登记的药物或干预包括Torvutatug samrotecan；Bevacizumab，当前状态为尚未开始招募。登记地点显示中国北京、广东省、广州、武汉有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Torvutatug samrotecan；Bevacizumab · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · 北京
- Research Site · 广东省
- Research Site · 广州
- Research Site · 武汉
公开的入选条件
- * Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
- * Provision of an archival FFPE tumour sample
- * Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
- * Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
- * Participants who received at least 6 cycles of PBC during the induction phase of their current line of treatment.
- * Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
- * Participants with non-progressive disease upon completion of PBC in their current line of treatment.
- * Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07816666；登记信息更新于 2026-09-14。